Spruce Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Spruce Biosciences, Inc. carries a market capitalization of 67.30M, placing it among publicly traded companies globally. Its enterprise value stands at 8.40M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 67.30M |
| Enterprise Value | 8.40M |
Share Statistics
Spruce Biosciences, Inc. currently has 1.37M shares outstanding.
| Shares Outstanding | 1.37M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.18 |
| P/TBV Ratio | 1.60 |
| P/FCF Ratio | -1.89 |
| P/OCF Ratio | -1.89 |
Financial Position
Spruce Biosciences, Inc. maintains a current ratio of 4.67, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.56, indicating elevated leverage, while an interest coverage ratio of -46.35 demonstrates limited ability to service its debt obligations.
| Current Ratio | 4.67 |
| Quick Ratio | 4.59 |
| Debt / Equity | 20.56 |
| Debt / EBITDA | -0.21 |
| Interest Coverage | -46.35 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -84.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Spruce Biosciences, Inc.'s stock has gained approximately 905.12295% over the past 52 weeks. The 50-day moving average sits at 58.83, while the 200-day moving average is 69.18.
| Beta (5Y) | N/A |
| 52-Week Price Change | 905.12295% |
| 50-Day Moving Average | 58.83 |
| 200-Day Moving Average | 69.18 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -33.74M, while operating income came in at -34.01M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -34.01M |
| Pretax Income | -37.19M |
| Net Income | -37.19M |
| EBITDA | -33.74M |
| EBIT | -34.01M |
| Earnings Per Share (EPS) | -43.90 |
Balance Sheet
Spruce Biosciences, Inc. holds 54.08M in cash and equivalents against 7.12M in total debt, resulting in a net debt position of -47.62M. Total book value stands at -301.50M, with working capital of 43.25M providing operational flexibility.
| Cash & Cash Equivalents | 54.08M |
| Total Debt | 7.12M |
| Net Debt | -47.62M |
| Equity (Book Value) | -301.50M |
| Book Value Per Share | -355.90 |
| Working Capital | 43.25M |
Cash Flow
Spruce Biosciences, Inc. produced -29.33M in operating cash flow over the past twelve months. After subtracting -10,000.00 in capital expenditures, free cash flow totaled -29.34M - equivalent to -34.64 per share.
| Operating Cash Flow | -29.33M |
| Capital Expenditures | -10,000.00 |
| Free Cash Flow | -29.34M |
| FCF Per Share | -34.64 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -104.42 |
| FCF Yield | -52.96 |
Stock Splits
Spruce Biosciences, Inc.'s most recent stock split took place on August 5, 2025 with a 75:1 split ratio.
| Last Split Date | 8/5/2025 |
| Split Ratio | 75:1 |
Scores
Spruce Biosciences, Inc. posts an Altman Z-Score of -7.05, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -7.05 |